Source: https://vxlabels.com/lib/vaccines/vax/menactra-1/
Timestamp: 2020-02-23 00:50:54
Document Index: 546047755

Matched Legal Cases: ['§ 12', '§ 15', '§ 10', '§ 10', '§ 17', '§ 14', '§ 12']

Menactra: Vaccine Information from the FDA, via VxLabels.com
Vaccine Information: Menactra
Sanofi Pasteur Inc. 23 July 2019
MENACTRA- neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen, neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen, neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen and neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen injection, solution
Menactra® , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitidis serogroup B disease.
Menactra is a clear to slightly turbid solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If any of these conditions exist, the vaccine should not be administered.
Menactra is administered as a 0.5 mL dose by intramuscular injection. Do not administer this product intravenously or subcutaneously.
Individuals 2 through 55 years of age, Menactra is given as a single dose.
Menactra is a solution supplied in 0.5 mL single-dose vials. [See Description (11) for a complete listing of ingredients.]
Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197 -containing vaccine, or to any component of Menactra [see Description (11)].
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra. The decision to give Menactra should take into account the potential benefits and risks.
GBS has been reported in temporal relationship following administration of Menactra (1) (2). The risk of GBS following Menactra vaccination was evaluated in a post-marketing retrospective cohort study [see Post-Marketing Experience (6.2)].
Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to Menactra.
Complement Deficiency Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by N meningitidis , including invasive disease caused by serogroups A, C, Y and W-135, even if they develop antibodies following vaccination with Menactra [see Clinical Pharmacology (12)].
Menactra may not protect all recipients.
Syncope (fainting) has been reported following vaccination with Menactra. Procedures should be in place to prevent falling injury and manage syncopal reactions.
The safety of Menactra was evaluated in four clinical studies that enrolled 3721 participants who received Menactra at 9 and 12 months of age. At 12 months of age these children also received one or more other recommended vaccines [Measles, Mumps, Rubella and Varicella Virus Vaccine Live (MMRV) or Measles, Mumps, and Rubella Virus Vaccine (MMR) and Varicella Virus Vaccine Live (V) each manufactured by Merck & Co., Inc., Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) manufactured by Wyeth Pharmaceuticals Inc. (PCV7), Hepatitis A Vaccine manufactured by Merck & Co., Inc. (HepA). A control group of 997 children was enrolled at 12 months of age and received two or more childhood vaccines [MMRV (or MMR+V), PCV7, HepA] at 12 months of age [see Concomitant Vaccine Administration (14.3)]. Three percent of individuals received MMR and V, instead of MMRV, at 12 months of age.
The primary safety study was a controlled trial that enrolled 1256 children who received Menactra at 9 and 12 months of age. At 12 months of age these children received MMRV (or MMR+V), PCV7 and HepA. A control group of 522 children received MMRV, PCV7 and HepA. Of the 1778 children, 78% of participants (Menactra, N=1056; control group, N=322) were enrolled at United States (US) sites and 22% at a Chilean site. (Menactra, N=200; control group, N=200).
The safety of Menactra was evaluated in eight clinical studies that enrolled 10,057 participants aged 2-55 years who received Menactra and 5,266 participants who received Menomune® – A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined. There were no substantive differences in demographic characteristics between the vaccine groups. Among Menactra recipients 2-55 years of age 24.0%, 16.2%, 40.4% and 19.4% were in the 2-10, 11-14, 15-25 and 26-55-year age groups, respectively. Among Menomune – A/C/Y/W-135 recipients 2-55 years of age 42.3%, 9.3%, 30.0% and 18.5% were in the 2-10, 11-14, 15-25 and 26-55-year age groups, respectively. The three primary safety studies were randomized, active-controlled trials that enrolled participants 2-10 years of age (Menactra, N=1713; Menomune – A/C/Y/W-135, N=1519), 11-18 years of age (Menactra, N=2270; Menomune – A/C/Y/W-135, N=972) and 18-55 years of age (Menactra, N=1384; Menomune – A/C/Y/W-135, N=1170), respectively. Of the 3232 children 2-10 years of age, 68% of participants (Menactra, N=1164; Menomune – A/C/Y/W-135, N=1031) were enrolled at US sites and 32% (Menactra, N=549; Menomune – A/C/Y/W-135, N=488) of participants at a Chilean site. The median ages in the Chilean and US subpopulations were 5 and 6 years, respectively. All adolescents and adults were enrolled at US sites. As the route of administration differed for the two vaccines (Menactra given intramuscularly, Menomune – A/C/Y/W-135 given subcutaneously), study personnel collecting the safety data differed from personnel administering the vaccine.
In an open-label trial conducted in the US, 834 individuals were enrolled to receive a single dose of Menactra 4-6 years after a prior dose. The median age of participants was 17.1 years at the time of the booster dose.
Participants were monitored after each vaccination for 20 or 30 minutes for immediate reactions, depending on the study. Solicited injection site and systemic reactions were recorded in a diary card for 7 consecutive days after each vaccination. Participants were monitored for 28 days (30 days for infants and toddlers) for unsolicited adverse events and for 6 months post-vaccination for visits to an emergency room, unexpected visits to an office physician, and serious adverse events. Unsolicited adverse event information was obtained either by telephone interview or at an interim clinic visit. Information regarding adverse events that occurred in the 6-month post-vaccination time period was obtained via a scripted telephone interview.
Serious adverse events (SAEs) were reported during a 6-month time period following vaccinations in individuals 9 months through 55 years of age. In children who received Menactra at 9 months and at 12 months of age, SAEs occurred at a rate of 2.0% — 2.5%. In participants who received one or more childhood vaccine(s) (without co-administration of Menactra) at 12 months of age, SAEs occurred at a rate of 1.6% — 3.6%, depending on the number and type of vaccines received. In children 2-10 years of age, SAEs occurred at a rate of 0.6% following Menactra and at a rate of 0.7% following Menomune – A/C/Y/W-135. In adolescents 11 through 18 years of age and adults 18 years through 55 years of age, SAEs occurred at a rate of 1.0% following Menactra and at a rate of 1.3% following Menomune – A/C/Y/W-135. In adolescents and adults, SAEs occurred at a rate of 1.3% following booster vaccination with Menactra.
The most frequently reported solicited injection site and systemic adverse reactions in US children aged 2-10 years of age (Table 2) were injection site pain and irritability. Diarrhea, drowsiness, and anorexia were also common.
The most commonly reported solicited injection site and systemic adverse reactions in adolescents, ages 11-18 years (Table 3), and adults, ages 18-55 years (Table 4), after a single dose were injection site pain, headache and fatigue. Except for redness in adults, injection site reactions were more frequently reported after Menactra vaccination than after Menomune – A/C/Y/W-135 vaccination.
Menactra at 9 months of age
Menactra + PCV7*+ MMRV † + HepA ‡ at 12 months of age
PCV7*+ MMRV †+ HepA ‡ at 12 months of age
N §=998 — 1002
N §=898 — 908
N §=302 — 307
PCV7 (Prevnar®) = Pneumococcal 7-valent Conjugate Vaccine
MMRV (ProQuad®) = Measles, Mumps, Rubella and Varicella Virus Vaccine Live
HepA (VAQTA®) = Hepatitis A Vaccine, Inactivated
N = The number of participants with available data.
Grade 2: cries and protests when injection site is touched, Grade 3: cries when injected limb is moved, or the movement of the injected limb is reduced.
Grade 2: ≥1.0 inches to <2.0 inches, Grade 3: ≥2.0 inches.
Grade 2: requires increased attention, Grade 3: inconsolable.
Grade 2: 1 to 3 hours, Grade 3: >3 hours.
Grade 2: not interested in surroundings or did not wake up for a feed/meal, Grade 3: sleeping most of the time or difficult to wake up.
Grade 2: missed 1 or 2 feeds/meals completely, Grade 3: refuses ≥3 feeds/meals or refuses most feeds/meals.
Grade 2: 2 to 5 episodes per 24 hours, Grade 3: ≥6 episodes per 24 hours or requiring parenteral hydration.
Grade 2: >38.5°C to ≤39.5°C, Grade 3: >39.5°C.
Tenderness ¶
Menactra Site 37.4 4.3 0.6 48.5 7.5 1.3 - - -
PCV7 Site - - - 45.6 9.4 1.6 45.7 8.3 0.3
MMRV Site - - - 38.9 7.1 1.0 43.0 5.2 0.0
HepA Site - - - 43.4 8.7 1.4 40.9 4.6 0.3
Erythema #
Menactra Site 30.2 2.5 0.3 30.1 1.3 0.1 - - -
PCV7 Site - - - 29.4 2.6 0.2 32.6 3.0 0.7
MMRV Site - - - 22.5 0.9 0.3 33.2 5.9 0.0
HepA Site - - - 25.1 1.1 0.0 26.6 0.7 0.0
Swelling #
Menactra Site 16.8 0.9 0.2 16.2 0.9 0.1 - - -
PCV7 Site - - - 19.5 1.3 0.4 16.6 1.3 0.7
MMRV Site - - - 12.1 0.4 0.1 14.1 0.3 0.0
HepA Site - - - 16.4 0.7 0.2 13.5 0.0 0.3
Irritability Þ 56.8 23.1 2.9 62.1 25.7 3.7 64.8 28.7 4.2
Abnormal crying ß 33.3 8.3 2.0 40.0 11.5 2.4 39.4 10.1 0.7
Drowsiness à 30.2 3.5 0.7 39.8 5.3 1.1 39.1 5.2 0.7
Appetite loss è 30.2 7.1 1.2 35.7 7.6 2.6 31.9 6.5 0.7
Vomiting ð 14.1 4.6 0.3 11.0 4.4 0.2 9.8 2.0 0.0
Fever ø 12.2 4.5 1.1 24.5 11.9 2.2 21.8 7.3 2.6
Menomune – A/C/Y/W-135
N *=1156 — 1157
N *=1027
N = The total number of participants reporting at least one solicited reaction. The median age of participants was 6 years in both vaccine groups.
Grade 2: interferes with normal activities, Grade 3: disabling, unwilling to move arm.
Grade 2: 1.0-2.0 inches, Grade 3: >2.0 inches.
Grade 2: 1-3 hours duration, Grade 3: >3 hours duration.
Grade 2: 3-4 episodes, Grade 3: ≥5 episodes.
Grade 2: interferes with normal activities, Grade 3: disabling, unwilling to engage in play or interact with others.
Grade 2: skipped 2 meals, Grade 3: skipped ≥3 meals.
Grade 2: decreased range of motion due to pain or discomfort, Grade 3: unable to move major joints due to pain.
Oral equivalent temperature; Grade 2: 38.4°C to 39.4ºC, Grade 3: ≥39.5ºC.
Grade 2: 2 episodes, Grade 3: ≥3 episodes.
Pain † 45.0 4.9 0.3 26.1 2.5 0.0
Redness ‡ 21.8 4.6 3.9 7.9 0.5 0.0
Induration ‡ 18.9 3.4 1.4 4.2 0.6 0.0
Swelling ‡ 17.4 3.9 1.9 2.8 0.3 0.0
Irritability § 12.4 3.0 0.3 12.2 2.6 0.6
Diarrhea ¶ 11.1 2.1 0.2 11.8 2.5 0.3
Drowsiness # 10.8 2.7 0.3 11.2 2.5 0.5
Anorexia Þ 8.2 1.7 0.4 8.7 1.3 0.8
Arthralgia ß 6.8 0.5 0.2 5.3 0.7 0.0
Fever à 5.2 1.7 0.3 5.2 1.7 0.2
Rash è 3.4 - - 3.0 - -
Vomiting ð 3.0 0.7 0.3 2.7 0.7 0.6
Seizure è 0.0 - - 0.0 - -
Table 3: Percentage of Participants 11 Years Through 18 Years of Age Reporting Solicited Adverse Reactions Within 7 Days Following Vaccine Administration With a Single Dose
N *=2264 — 2265
N *=970
Grade 2: interferes with or limits usual arm movement, Grade 3: disabling, unable to move arm.
Denotes p <0.05 level of significance. The p -values were calculated for each category and severity using Chi Square test.
Grade 2: interferes with normal activities, Grade 3: requiring bed rest.
Oral equivalent temperature; Grade 2: 38.5°C to 39.4ºC, Grade 3: ≥39.5ºC.
Pain † 59.2‡ 12.8‡ 0.3 28.7 2.6 0.0
Induration § 15.7‡ 2.5‡ 0.3 5.2 0.5 0.0
Redness § 10.9‡ 1.6‡ 0.6‡ 5.7 0.4 0.0
Swelling § 10.8‡ 1.9‡ 0.5‡ 3.6 0.3 0.0
Headache ¶ 35.6‡ 9.6‡ 1.1 29.3 6.5 0.4
Fatigue ¶ 30.0‡ 7.5 1.1‡ 25.1 6.2 0.2
Malaise ¶ 21.9‡ 5.8‡ 1.1 16.8 3.4 0.4
Arthralgia ¶ 17.4‡ 3.6‡ 0.4 10.2 2.1 0.1
Diarrhea # 12.0 1.6 0.3 10.2 1.3 0.0
Anorexia Þ 10.7‡ 2.0 0.3 7.7 1.1 0.2
Chills ¶ 7.0‡ 1.7‡ 0.2 3.5 0.4 0.1
Fever ß 5.1 ‡ 0.6 0.0 3.0 0.3 0.1
Vomiting à 1.9 0.4 0.3 1.4 0.5 0.3
Rash è 1.6 - - 1.4 - -
Table 4: Percentage of Participants 18 Years Through 55 Years of Age Reporting Solicited Adverse Reactions Within 7 Days Following Vaccine Administration With a Single Dose
N *=1371
N *=1159
Oral equivalent temperature; Grade 2: 39.0°C to 39.9ºC, Grade 3: ≥40.0ºC.
Pain † 53.9‡ 11.3‡ 0.2 48.1 3.3 0.1
Induration § 17.1‡ 3.4‡ 0.7‡ 11.0 1.0 0.0
Redness § 14.4 2.9 1.1‡ 16.0 1.9 0.1
Swelling § 12.6‡ 2.3‡ 0.9‡ 7.6 0.7 0.0
Headache ¶ 41.4 10.1 1.2 41.8 8.9 0.9
Fatigue ¶ 34.7 8.3 0.9 32.3 6.6 0.4
Malaise ¶ 23.6 6.6‡ 1.1 22.3 4.7 0.9
Arthralgia ¶ 19.8‡ 4.7‡ 0.3 16.0 2.6 0.1
Diarrhea # 16.0 2.6 0.4 14.0 2.9 0.3
Anorexia Þ 11.8 2.3 0.4 9.9 1.6 0.4
Chills ¶ 9.7‡ 2.1‡ 0.6‡ 5.6 1.0 0.0
Vomiting ß 2.3 0.4 0.2 1.5 0.2 0.4
Fever à 1.5‡ 0.3 0.0 0.5 0.1 0.0
Rash è 1.4 - - 0.8 - -
Solicited Adverse Events in a Booster Vaccination Study
For a description of the study design and number of participants, [see Clinical Trials Experience, Booster Vaccination Study (6.1)]. The most common solicited injection site and systemic reactions within 7 days of vaccination were pain (60.2%) and myalgia (42.8%), respectively. Overall rates of solicited injection site reactions and solicited systemic reactions were similar to those observed in adolescents and adults after a single Menactra dose. The majority of solicited reactions were Grade 1 or 2 and resolved within 3 days.
For a description of the study design and number of participants, [see Clinical Trials Experience (6.1), Concomitant Vaccine Administration (14.3)]. In the primary safety study, 1378 US children were enrolled to receive Menactra alone at 9 months of age and Menactra plus one or more other routinely administered vaccines (MMRV, PCV7 and HepA) at 12 months of age (N=961). Another group of children received two or more routinely administered vaccines (MMRV, PCV7 and HepA) (control group, n=321) at 12 months of age. The frequency of occurrence of solicited adverse events is presented in Table 1. Participants who received Menactra and the concomitant vaccines at 12 months of age described above reported similar frequencies of tenderness, redness and swelling at the Menactra injection site and at the concomitant vaccine injection sites. Tenderness was the most frequent injection site reaction (48%, 39%, 46% and 43% at the Menactra, MMRV, PCV7 and HepA sites, respectively). Irritability was the most frequent systemic reaction, reported in 62% of recipients of Menactra plus concomitant vaccines, and 65% of the control group [see Concomitant Vaccine Administration (14.3)].
In a randomized, parallel group, US multi-center clinical trial conducted in children 4 through 6 years of age, Menactra was administered as follows: 30 days after concomitant DAPTACEL® , Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, (DTaP), manufactured by Sanofi Pasteur Limited + IPOL® , Poliovirus Vaccine Inactivated, (IPV), manufactured by Sanofi Pasteur SA [Group A]; concomitantly with DAPTACEL followed 30 days later by IPV [Group B]; concomitantly with IPV followed 30 days later by DAPTACEL [Group C]. Solicited injection site and systemic reactions were recorded in a diary card for 7 consecutive days after each vaccination. For all study groups, the most frequently reported solicited local reaction at the Menactra site was pain: 52.2%, 60.9% and 56.0% of participants in Groups A, B and C, respectively. For all study groups, the most frequently reported systemic reaction following the administration of Menactra alone or with the respective concomitant vaccines was myalgia: 24.2%, 37.3% and 26.7% of participants in Groups A, B and C, respectively. Fever >39.5ºC occurred at <1.0% in all groups [see Concomitant Vaccine Administration (14.3)].
In a clinical study, rates of local and systemic reactions after Menactra and Tetanus and Diphtheria Toxoid Adsorbed (Td) vaccine manufactured by Sanofi Pasteur Inc. were compared [see Drug Interactions (7), and Concomitant Vaccine Administration (14.3) for study description]. Injection site pain was reported more frequently after Td vaccination than after Menactra vaccination (71% versus 53%). The overall rate of systemic adverse events was higher when Menactra and Td vaccines were given concomitantly than when Menactra was administered 28 days after Td vaccine (59% versus 36%). In both groups, the most common reactions were headache (Menactra + Td vaccine, 36%; Td vaccine + Placebo, 34%; Menactra alone, 22%) and fatigue (Menactra + Td vaccine, 32%; Td vaccine + Placebo, 29%; Menactra alone, 17%). Fever ≥40.0ºC occurred at ≤0.5% in all groups.
In a clinical study, rates of local and systemic reactions after Menactra and Typhim Vi® [Typhoid Vi Polysaccharide Vaccine] (Typhoid), produced by Sanofi Pasteur SA were compared [see Drug Interactions (7) and Concomitant Vaccine Administration (14.3)] for a description of the concomitantly administered vaccine, study design and number of participants. More participants experienced pain after Typhoid vaccination than after Menactra vaccination (Typhoid + Placebo, 76% versus Menactra + Typhoid, 47%). The majority (70%-77%) of injection site solicited reactions for both groups at either injection site were reported as Grade 1 and resolved within 3 days post-vaccination. In both groups, the most common systemic reaction was headache (Menactra + Typhoid, 41%; Typhoid + Placebo, 42%; Menactra alone, 33%) and fatigue (Menactra + Typhoid, 38%; Typhoid + Placebo, 35%; Menactra alone, 27%). Fever ≥40.0ºC and seizures were not reported in either group.
Vaccine brand names beginning with the letter ‘M’ (Menactra).
Vaccine types beginning with the letter ‘N’ (NEISSERIA MENINGITIDIS GROUP A CAPSULAR POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE ANTIGEN, NEISSERIA MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE ANTIGEN,…).
https://vxlabels.com/lib/vaccines/vax/menactra-1/